STOCK TITAN

[4] – Scharen-Guivel Hilda Frederique (CIK 0001950129)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

IRADIMED Corporation (IRMD) director reported RSU vesting and conversion. On 10/14/2025, 1,767 restricted stock units converted into 1,767 shares of common stock at $0 (Transaction Code M). Following the transaction, the director directly holds 6,496 shares.

The RSUs were granted on 10/14/2022 under the 2014 Equity Incentive Plan and vest in three equal annual installments beginning 10/14/2023, delivering one share for each unit that vests.

IRADIMED Corporation (IRMD) il direttore ha riferito l'acquisizione e la conversione di RSU. Il 14/10/2025, 1.767 restricted stock units convertiti in 1.767 azioni comuni al $0 (Codice di transazione M). Dopo la transazione, il direttore detiene direttamente 6.496 azioni.

Le RSU sono state concesse il 14/10/2022 ai sensi del Piano di Incentivi Azionari 2014 e vestono in tre rate annuali uguali a partire dal 14/10/2023, consegnando un'azione per ogni unità che matura.

IRADIMED Corporation (IRMD) director informó sobre la adquisición y conversión de RSU. El 14/10/2025, 1.767 unidades de acciones restringidas se convirtieron en 1.767 acciones ordinarias a $0 (Código de Transacción M). Tras la operación, el director posee directamente 6.496 acciones.

Las RSU fueron concedidas el 14/10/2022 bajo el Plan de Incentivos de Acciones 2014 y vencen en tres cuotas anuales iguales a partir del 14/10/2023, entregando una acción por cada unidad que vence.

IRADIMED Corporation (IRMD) 이사는 RSU의 취득 및 전환을 보고했습니다. 2025년 10월 14일1,767개의 제한 주식 단위$0보통주 1,767주로 전환되었습니다(거래 코드 M). 거래 후 이사는 직접 6,496주를 보유합니다.

RSU는 2022년 10월 14일에 2014년 주식 보상 계획에 따라 부여되었으며, 2023년 10월 14일부터 매년 같은 규모로 3회에 걸쳐 vesting되어, vesting되는 각 단위당 한 주가 지급됩니다.

IRADIMED Corporation (IRMD) le directeur a signalé la prise des RSU et leur conversion. Le 14/10/2025, 1 767 unités d'actions restreintes ont été converties en 1 767 actions ordinaires à $0 (Code de transaction M). Après l'opération, le directeur détient directement 6 496 actions.

Les RSU ont été accordées le 14/10/2022 dans le cadre du Plan d'incitation en actions 2014 et se vissent en trois versements annuels égaux à partir du 14/10/2023, livrant une action pour chaque unité qui se vissent.

IRADIMED Corporation (IRMD) Direktor meldete RSU-Vesting und -Umwandlung. Am 14.10.2025 wurden 1.767 Restricted Stock Units in 1.767 Stammaktien zu $0 (Transaktionscode M) umgewandelt. Nach der Transaktion hält der Direktor direkt 6.496 Aktien.

Die RSU wurden am 14.10.2022 gemäß dem Equity Incentive Plan 2014 gewährt und vesten in drei gleichen jährlichen Raten beginnend am 14.10.2023, wobei eine Aktie pro verfallender Einheit ausgegeben wird.

IRADIMED Corporation (IRMD) قد أبلغ مدير المجلس عن تقيد RSU وتحويلها. في 14/10/2025، 1,767 وحدة أسهم مقيدة تحولت إلى 1,767 سهماً عادياً بسعر $0 (رمز المعاملة M). بعد المعاملة، يملك المدير مباشرةً 6,496 سهماً.

تم منح RSU في 14/10/2022 بموجب خطة الحوافز الأسهمية لعام 2014 وتُ vest في ثلاث دفعات سنوية متساوية بدءاً من 14/10/2023، مع تسليم سهم واحد لكل وحدة عند vesting.

IRADIMED Corporation (IRMD) 董事报告了 RSU 的归属与转换。于 2025/10/141,767 个受限股票单位转换为 1,767 股普通股,交易代码为 M,价格为 $0。交易完成后,该董事直接持有 6,496 股

该 RSU 于 2022/10/14 根据 2014 年股权激励计划授予,并在 2023/10/14 起以 三个等额年度分期 vesting,每个单位 vesting 时发放一股。

Positive
  • None.
Negative
  • None.

IRADIMED Corporation (IRMD) il direttore ha riferito l'acquisizione e la conversione di RSU. Il 14/10/2025, 1.767 restricted stock units convertiti in 1.767 azioni comuni al $0 (Codice di transazione M). Dopo la transazione, il direttore detiene direttamente 6.496 azioni.

Le RSU sono state concesse il 14/10/2022 ai sensi del Piano di Incentivi Azionari 2014 e vestono in tre rate annuali uguali a partire dal 14/10/2023, consegnando un'azione per ogni unità che matura.

IRADIMED Corporation (IRMD) director informó sobre la adquisición y conversión de RSU. El 14/10/2025, 1.767 unidades de acciones restringidas se convirtieron en 1.767 acciones ordinarias a $0 (Código de Transacción M). Tras la operación, el director posee directamente 6.496 acciones.

Las RSU fueron concedidas el 14/10/2022 bajo el Plan de Incentivos de Acciones 2014 y vencen en tres cuotas anuales iguales a partir del 14/10/2023, entregando una acción por cada unidad que vence.

IRADIMED Corporation (IRMD) 이사는 RSU의 취득 및 전환을 보고했습니다. 2025년 10월 14일1,767개의 제한 주식 단위$0보통주 1,767주로 전환되었습니다(거래 코드 M). 거래 후 이사는 직접 6,496주를 보유합니다.

RSU는 2022년 10월 14일에 2014년 주식 보상 계획에 따라 부여되었으며, 2023년 10월 14일부터 매년 같은 규모로 3회에 걸쳐 vesting되어, vesting되는 각 단위당 한 주가 지급됩니다.

IRADIMED Corporation (IRMD) le directeur a signalé la prise des RSU et leur conversion. Le 14/10/2025, 1 767 unités d'actions restreintes ont été converties en 1 767 actions ordinaires à $0 (Code de transaction M). Après l'opération, le directeur détient directement 6 496 actions.

Les RSU ont été accordées le 14/10/2022 dans le cadre du Plan d'incitation en actions 2014 et se vissent en trois versements annuels égaux à partir du 14/10/2023, livrant une action pour chaque unité qui se vissent.

IRADIMED Corporation (IRMD) Direktor meldete RSU-Vesting und -Umwandlung. Am 14.10.2025 wurden 1.767 Restricted Stock Units in 1.767 Stammaktien zu $0 (Transaktionscode M) umgewandelt. Nach der Transaktion hält der Direktor direkt 6.496 Aktien.

Die RSU wurden am 14.10.2022 gemäß dem Equity Incentive Plan 2014 gewährt und vesten in drei gleichen jährlichen Raten beginnend am 14.10.2023, wobei eine Aktie pro verfallender Einheit ausgegeben wird.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Scharen-Guivel Hilda Frederique

(Last) (First) (Middle)
C/O IRADIMED CORPORATION
12705 INGENUITY DRIVE

(Street)
ORLANDO FL 32826

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
IRADIMED CORP [ IRMD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/14/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/14/2025 M 1,767 A (1) 6,496 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (1) 10/14/2025 M 1,767 (2) (2) Common Stock 1,767 $0 0 D
Explanation of Responses:
1. Restricted stock units convert into common stock on a one-for-one basis.
2. On October 14, 2022, the reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in three equal annual installments beginning on October 14, 2023. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.
/s/ Hilda F. Scharen-Guivel 10/15/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Iradimed Corp

NASDAQ:IRMD

IRMD Rankings

IRMD Latest News

IRMD Latest SEC Filings

IRMD Stock Data

967.36M
8.04M
36.81%
59.44%
1.19%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
ORLANDO